Pharmacoeconomic evaluation of ceftazidime + avibactam administration in the treatment of nosocomial pneumonia caused by carbapenem-resistant Enterobacteriacea and complicated by bacteremia
Medical Technologies. Assessment and Choice · 2020
DOI: 10.17116/medtech20204002150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Technologies. Assessment and Choice, 2020. Verfasst von S.K. Zyryanov und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Zyryanov, S., & Dyakov, I. (2020). Pharmacoeconomic evaluation of ceftazidime + avibactam administration in the treatment of nosocomial pneumonia caused by carbapenem-resistant Enterobacteriacea and complicated by bacteremia. Medical Technologies. Assessment and Choice. https://doi.org/10.17116/medtech20204002150
Vancouver
Zyryanov S, Dyakov I. Pharmacoeconomic evaluation of ceftazidime + avibactam administration in the treatment of nosocomial pneumonia caused by carbapenem-resistant Enterobacteriacea and complicated by bacteremia. Medical Technologies. Assessment and Choice. 2020. doi:10.17116/medtech20204002150
BibTeX
@article{Zyryanov2020,
author = {Zyryanov, S.K. and Dyakov, I.N.},
title = {Pharmacoeconomic evaluation of ceftazidime + avibactam administration in the treatment of nosocomial pneumonia caused by carbapenem-resistant Enterobacteriacea and complicated by bacteremia},
journal = {Medical Technologies. Assessment and Choice},
year = {2020},
doi = {10.17116/medtech20204002150}
}
EUVIMED